Nondaily Smokers' Changes in Cigarette Consumption With Very Low-Nicotine-Content Cigarettes: A Randomized Double-blind Clinical Trial.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

To compare cigarette consumption in ITS receiving very low-nicotine-content cigarettes (VLNCCs) or identical normal-nicotine-content cigarettes (NNCCs).

Why It Was Studied

The US Food and Drug Administration is considering limiting cigarettes to very low nicotine levels.

Who Took Part

According to the abstract, 297 individuals were involved.

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

Volunteer ITS not planning to quit were recruited via media.

Overall, 297 individuals enrolled, and 238 were randomized.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

This randomized double-blind clinical trial was conducted from June 2015 to July 2017 at a single US site.

What Was Measured

The US Food and Drug Administration is considering limiting cigarettes to very low nicotine levels.

PubMed files the paper under topics including Cigarette Smoking, Nicotine, Outcome Assessment, Health Care, Smoking Cessation and Tobacco Products.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide) in 297 individuals.

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (JAMA psychiatry), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.